DNA vaccines are being investigated as targeted immunotherapy for melanoma as well as for other cancers. Both viral and nonviral methods of gene transfer are being used as vaccines in preclinical and in preliminary clinical trials (1 -6) . Although viral vectors can achieve high transgene expression (7) , the immunogenicity of viral vectors limits the use of these vectors as DNA vaccines (8, 9) .
Particle-mediated epidermal delivery (PMED) is a method of nonviral gene transfer that has been effectively used as a DNA vaccine in preclinical studies (10, 11) . This technique uses a burst of helium gas to deliver microscopic gold particles coated with DNA into cells. Thus, PMED can (a) target delivery of the vaccine to a specific anatomic location, (b) avoid the potential risks associated with viral infection, (c) transfect a variety of cell lineages without the need for concomitant cell division, and (d) deliver multiple genes simultaneously (12 -18) . Along with these benefits, PMED often confers levels of transgene expression that are significantly greater than other methods of nonviral DNA transfer (19) . Moreover, the safety of PMED in humans has been suggested in phase I clinical trials for infectious disease (20 -22) . However, the use of in vivo PMED as a vaccine for cancer patients has not been reported previously.
The stimulation of effective antimelanoma T-cell immunity may require delivery of one or more genes to induce target expression of an immunogenic melanoma-associated antigen as well as delivery of a second gene to stimulate an increase in antigen-presenting cells in human epidermis. We selected the genes for gp100 and granulocyte macrophage colonystimulating factor (GM-CSF) to achieve these two aims, respectively. Here, we report the clinical toxicity as well as biological activity of immunization using particle-mediated delivery of genes for gp100 and GM-CSF into uninvolved skin of patients with melanoma.
Materials and Methods

Clinical protocol
Patients. From May 1999 to February 2000, 12 patients with melanoma were enrolled in this trial (University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Protocol CO98601). The study was approved by the University of Wisconsin Human Subjects Committee. All patients signed informed consent forms and registered with the Biostatistics Registration Desk before treatment.
All patients had biopsy-proven malignant melanoma with one of the following characteristics: (a) measurable or evaluable metastatic disease or (b) no evidence of disease if the patient had surgical resection of two or more local or regional recurrences or surgical resection of a distant metastasis. Patients could have received no more than two prior treatment regimens containing chemotherapy (any prior number of immunotherapy treatments was acceptable). Patients also must have had an Eastern Cooperative Oncology Group Performance Status of 0 or 1 and a life expectancy greater than 3 months. Laboratory eligibility criteria included normal hematologic and chemistry parameters.
Patients were excluded from this study if they had received treatment with chemotherapy, radiotherapy, or immunotherapy within 1 month of study entry or prior radiotherapy to potential vaccine sites. Patients also were excluded if they had significant intercurrent illnesses or an ongoing requirement for corticosteroid therapy.
Plasmid DNA description, preparation, and delivery. Each vaccine was administered using the PowderJect XR1 (formerly PowderJect Device model 0895). PowderJect XR1 is a gas discharge device used to deliver microscopic gold particles coated with vector DNA directly into target cells. The technical aspects of this technique have been described previously (19, 21) . In this study, the PowderJect XR1 device delivered either a human GM-CSF expression vector pWRG3218 or a gp100 expression vector pWRG1644 at a constant delivery pressure of 500 p.s.i. Each pulse delivered by the device contained 0.25 Ag plasmid DNA per 250 Ag gold. The construction of these plasmids has been described previously (10, 11) .
Study design. Six patients were to be enrolled in each treatment group. A two-level dose escalation schedule was used, as determined by the number of vaccines administered (Table 1) . Three patients were enrolled to receive vaccinations at dose level 1. In the absence of significant toxicity [i.e., National Cancer Institute-Common Terminology Criteria (NCI-CTC) grade 3 toxicity lasting longer than 24 h or any grade 4 toxicity], three additional patients would be enrolled to receive vaccinations at dose level 2. Patients were to be sequentially enrolled into groups I, II, and III. The study was monitored by the Clinical Trials Monitoring Service, with data submitted to the Clinical Trials Monitoring Service at least once every 2 weeks. In addition, annual reports were submitted to the NCI, the device manufacturer (Powder-Ject Vaccines, Inc.), and the University of Wisconsin Human Subjects Committee.
All PMED treatments were administered in vivo to normal skin on either proximal arms, proximal legs, or on the back. Treatment sites were shaved and prepped with alcohol before vaccination. There was a minimal distance of 2 cm between any of the gene delivery sites. Each cycle of treatment with gp100 cDNA alone (treatment group I) involved a single ''pulse'' of DNA-coated gold beads to each normal skin site. A second cycle was given 3 weeks after the initial PMED treatments, and these two cycles constituted a complete course of therapy. In sum, gp100 PMED was to be given on days 1 and 22 of course 1 (abbreviated C1D1 and C1D22, respectively). Patients in treatment group II received a single pulse of GM-CSF cDNA-coated gold beads 3 days before PMED with cDNA for gp100 (administered on C1D1 and C1D4 for GM-CSF and gp100, respectively). The gp100 PMED was given to the GM-CSFtreated skin sites, and one GM-CSF skin site was observed without gp100 treatment for skin reaction to PMED with GM-CSF alone. A second cycle was given 3 weeks after the initial PMED treatments (C1D22 and C1D25 for GM-CSF and gp100, respectively). Treatment group III was scheduled to receive a single pulse of combined gp100 and GM-CSF cDNA-coated gold beads at the same time points as that for group I. For all groups, vaccine site biopsies were scheduled 2 (cycle 1) and 4 (cycle 2) days after gp100 PMED; this corresponds to C1D3 and C1D26 for groups I and III and C1D6 and C1D29 for group II. The remaining vaccine sites were left in place and evaluated clinically. Based on their response (see below), patients could receive a maximum of two courses of therapy.
Toxicity grading and assessment. Both local and systemic toxicity to the vaccine were assessed according to the NCI-CTC, version 2.0. A history and physical exam was obtained from each patient at baseline, then again on days 22 and 43 of each treatment course while on study. Laboratory toxicities were assessed regularly throughout the study period; these studies included a complete blood count, platelet count, WBC differential, prothrombin time, partial thromboplastin time, and standard liver and kidney function tests. To assess local toxicity from the vaccines, vaccine sites were examined regularly while patients were on study. These sites were graded for ''injection site reactions'' according (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , which was used to follow them throughout the study. c The number of skin sites treated in each cycle. Two cycles of treatment comprise a complete course of treatment. b One of the GM-CSF skin sites was observed for skin reaction to PMED with GM-CSF alone. The remaining GM-CSF sites received PMED with gp100 3 d following the GM-CSF treatment.
x Group III was planned, but due to early termination of the study this cohort was canceled. (see Results for details).
to the NCI-CTC, version 2.0. Long-term follow-up and toxicity assessments using each of these above-mentioned tests were planned at 3, 6, and 12 months after completion of the study, after which patients were followed clinically for disease progression and survival. Response criteria. Antitumor response criteria were applied to measurements obtained 6 weeks following initial vaccination by PMED (i.e., C1D43). Evaluation of antitumor responses included as appropriate physical examination, computed tomography scans, magnetic resonance imaging scans, photographs of sites that were not readily measurable, or other tests appropriate for the specific tumor sites. A complete response was defined as the total disappearance of all clinical evidence of disease for at least two measurement periods separated by at least 4 weeks. A partial response was defined as at least a 50% reduction in the size of all measurable tumor areas. Progressive disease was defined as an increase of >25% and at least 2 cm 2 in area of the original lesions or the development of any new lesion. Stable disease would be assigned if criteria were not met for either progressive disease or a complete response or partial response. Patients with stable disease or an objective complete response or partial response were permitted to receive a second course of treatment. Tumor evaluation was done again 6 weeks following the initial vaccine of course 2 (i.e., C2D43). Long-term evaluations were scheduled at 3, 6, and 12 months following completion of the study.
Clinical and laboratory immunologic monitoring
Autoimmune antibody titers. Sera were obtained from patients at baseline as well as at C1D43, C2D43, and 3-and 6-month followup visits and tested for the following autoantibodies: antinuclear antibodies (ANA), anti-ssDNA, anti-dsDNA, rheumatoid factor, anti-parietal cell, anti-mitochondrial, anti-thyroglobulin, and antimicrosomal antibodies. These serum markers were tested by the Immunology Laboratory at the University of Wisconsin Hospital and Clinics (Madison, WI). Kallestad HEp-2 immunofluorescence ANA kits (Bio-Rad Laboratories, Redmond, WA) were used to detect antinuclear and anticytoplasmic autoantibodies according to the manufacturer's recommendations. The intra-assay and interassay coefficient of variation for this assay is <10%. The between-run and within-run precision within the laboratory are less than one doubling dilution. Results for anti-ssDNA were reported as units per milliliter, whereas levels of the other antibodies were reported as titers.
Processing of vaccine site biopsies. During each treatment cycle, one site of gp100 cDNA PMED had a 6-mm punch biopsy as described in Study Design. The tissue was bisected, with one half placed in formalin fixative. The processing of this half of the biopsy specimen included paraffin embedding and microtome sectioning. The remaining half of the biopsy specimen, which was not formalin fixed, was bisected again. One half of this portion (i.e., one quarter of the total) was frozen in ornithine carbamyl transferase medium. The remaining half was used for protein extraction (see below).
Histochemistry
Of the fixed and embedded tissue, one section from each available sample was stained with H&E (Sigma-Aldrich, St. Louis, MO). These slides were assessed subjectively for tissue and cellular response to vaccination as well as objectively for penetration of gold beads. For the latter, the number of beads seen in up to two separate Â20 magnification or medium power fields (MPF) was counted and averaged for each tissue specimen. From this, the proportion of beads seen within the stratum corneum, the malphigian layer (the deeper portion of the epidermis that includes live cells), and the dermis was calculated.
Sections from vaccine biopsies also were used for immunohistochemical analysis for gp100 and CD1a. Immunohistochemistry for gp100 was done on biopsies from patients 1 to 3 using a monoclonal antibody against gp100 (clone HMB45; DAKO, Carpinteria, CA) at a dilution of 1:50. CD1a staining was done on all available specimens using a monoclonal antibody (clone O10; Santa Cruz Biotechnology, Santa Cruz, CA) at a dilution of 1:50. Development of antigen-specific staining was accomplished using the Universal LSAB2-HRP staining kit according to the manufacturer's recommendations (DAKO). Antibody diluent [1% bovine serum albumin in 0.05 mol/L Tris-HCl (pH 7.5)] alone and an isotype control (Sigma-Aldrich) were used for negative control samples; sections of melanoma (gp100) and normal skin (CD1a) were used as positive controls. Tissues from both experiments were counterstained with Harris' hematoxylin (Sigma-Aldrich). For CD1a staining, the number of positive cells seen in separate MPFs was counted and averaged for each specimen. Photomicrographs of representative samples from the CD1a experiments were taken using MicroSuite Pathology Edition, version 2.3 (Olympus; Center Valley, PA).
Protein extraction
The portion of skin biopsy used for protein extraction was placed in a microfuge tube and weighed, and then 3 mL protein extraction buffer [PBS with 0.5% Triton X-100 and 240 Ag/mL Pefablock protease inhibitor (Roche Applied Science, Indianapolis, IN)] per mg of tissue was added. The cells in this tissue were lysed by snap-freezing in liquid nitrogen and stored at À80jC. The presence of GM-CSF in these lysates was assessed by sandwich ELISA using the human GM-CSF DuoSet ELISA Development System (R&D Systems, Minneapolis, MN) according to the manufacturer's recommendations. A lysate dilution of 1:50 was used such that the resulting absorbances fell within the manufacturer's suggested standard curve (0-1,000 pg/mL).
Delayed-type hypersensitivity reactions. Delayed-type hypersensitivity (DTH) testing was done on day 40 for HLA-A2(+) patients (i.e., patients 1, 2, 6, and 8) with purified gp100 clinical grade peptide known to be recognized by gp100 reactive, HLA-A2 -restricted T cells (gp100:209-217; 210M). This peptide was inoculated i.d. on the back or on an extremity not treated with the in vivo PMED treatments. In addition, recall antigen testing with Candida and mumps proteins was done on all patients on day 40. On day 43, the DTH testing sites were examined, and any area of erythema, induration, or ulceration was measured with calipers. Erythema greater than 5 mm, induration greater than 5 mm, or any ulceration was considered a positive DTH reaction.
Intracellular cytokine and T-cell marker staining. Human peripheral blood lymphocytes (PBL) were collected at baseline, C1D22, and C1D43. PBLs were isolated by Ficoll (Sigma-Aldrich) and cryopreserved in 10% DMSO (Sigma-Aldrich). For the flow cytometric analyses, PBLs from HLA-A2(+) patients in group I (i.e., patients 1, 2, and 6), along with a positive control human tumor-infiltrating lymphocyte line (TIL 1250; gift provided by Dr. Bernard A. Fox, Earle A. Chiles Research Institute, Portland, OR), were thawed and rested 12 to 24 h in RPMI 1640 (HyClone, Logan, UT) with 10% fetal bovine serum (HyClone) at 37jC. After this rest period, 1 Â 10 6 PBLs per well in six-well plates were stimulated with Mel5 (American Type Culture Collection, Manassas, VA) cell lysates (obtained from three cycles of freeze/thaw in liquid nitrogen and a 37jC water bath followed by ultrasonication) or with 5 ng/mL phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 500 ng/mL ionomycin (Sigma-Aldrich) in RMPI 1640 + 10% fetal bovine serum. Control wells contained medium alone. Brefeldin A (BD Biosciences, San Jose, CA) was added to all cultures at a final concentration of 10 Ag/mL after 2 h of incubation at 37jC. Cells were collected after 6 h of total incubation and washed twice with RPMI 1640 + 10% fetal bovine serum. Cells were resuspended in PBS with 2% fetal bovine serum (fluorescence-activated cell sorting buffer) and transferred to 96-well round-bottomed plates at 1 Â 10 6 per well and incubated on ice for 20 min with FITC-labeled antihuman CD3 antibody or isotype control (BD Biosciences). The cells were washed twice in fluorescence-activated cell sorting buffer and permeabilized with 100 AL Cytofix/Cytoperm (BD Biosciences) on ice for 20 min. Following two washes with Perm Wash (BD Biosciences), cells were stained with allophycocyanin-labeled antihuman CD69 and phycoerythrin-labeled antihuman IFN-g antibodies or isotype controls at room temperature for 15 min. Cells were washed twice with Perm Wash and resuspended in fluorescence-activated cell sorting buffer before acquisition on a FACSCalibur (BD Biosciences) flow cytometer using CellQuest software (BD Biosciences).
Statistical methods
The primary end points of this study were to determine the safety and toxicity of in vivo PMED using the cDNA for gp100, alone or in combination with the cDNA for GM-CSF. Secondary end points included transgene expression in skin following vaccination, local and systemic immunologic assessments, and evidence of an antitumor effect. With a sample size of six patients per group, we can detect an effect size (mean difference times the SD of the effect) of two of these end points with 88% power at a two-sided 0.05 significance level according to Student's t test.
When analyzing the results of GM-CSF expression, we assigned a label of ''positive'' expression or ''negative'' expression based on the following. We determined the mean concentration among all normal skin samples. We then set as our cutoff this average plus two SDs. As such, all samples with a concentration below this value were deemed negative, whereas all those above this value were called positive. For the analysis of CD1a immunohistochemistry, the number of cells in two separate MPFs was counted (if inadequate tissue was available, only one MPF was used). The means of these numbers were used to determine the average response per MPF per biopsy. These values then were used to determine the mean cell counts among normal skin and vaccine sites from the respective study groups.
A two-tailed Fisher's exact test was used to assess the differences in event rates with regards to GM-CSF expression (negative versus positive) in vaccine site biopsies. Wilcoxon rank-sum test was used to assess the statistical significance of the observed differences in the level of bead penetration (epidermis versus dermis) after normalization of the proportion of bead penetration between groups and between two time points after PMED. To assess differences between the two treatment groups with respect to gold-bead penetration and CD1a + cells, Satterthwaite's t test was used, as the variances in the groups were assumed unequal given the relatively small and varied sample sizes [i.e., n < 13 for all groups analyzed; applied similarly previously (ref. 23) ]. Statistical analysis was done using R. Information on R can be found online. 12 
Results
Patient characteristics
Twelve patients were entered into this study; their pretreatment characteristics are shown in Table 2 . The median age of all patients at the time of enrollment was 48 years (range, 36-68 years). Five of the 12 patients were women. All patients enrolled had an Eastern Cooperative Oncology Group performance status of 0 or 1. All 12 patients had been treated surgically before entering, 10 had received prior immunotherapy, and 4 had received prior cytotoxic chemotherapy. The most common sites of metastatic disease were the lymph nodes, skin, or subcutaneous tissue (n = 8 with at least one of the above) and the lungs (n = 5). Four patients had no clinical evidence of disease at the time of study entry.
Treatment summary
The 12 patients were enrolled into two treatment groups. Group I received PMED of gp100 cDNA, whereas patients in group II received PMED of cDNA for GM-CSF followed 3 days later by cDNA for gp100. The dose levels for each treatment group are summarized in Table 1 . All vaccines were adminis-tered according to this predetermined schedule. None of the patients in any of the treatment groups experienced doselimiting toxicity.
This study was terminated earlier than anticipated after a cryptic 109-bp viral DNA sequence positioned after a stop codon in the backbone plasmid was identified by the device manufacturer. These plasmids were no longer used. Further, the early study closure resulted in cancellation of the planned group III patient cohort, and three study patients (patients 9-11) were eligible but not able to receive additional cycles of therapy. Therefore, 9 of 12 (75%) patients enrolled completed study therapy. Table 3 shows the total number of cycles of PMED administered to each patient.
Toxicity
Following PMED, skin sites were graded for ''injection site reactions'' according to the NCI-CTC, version 2.0. No patient experienced a vaccine-site reaction that was assessed as greater than grade 2 (data not shown). Both erythema and induration were nearly universal findings at the skin sites after PMED. A sensation of tingling or stinging, as well as pruritus, also was seen in both groups, although not as consistently throughout patients. Dry-scale formation and localized eschar formation (with occasional mild ulceration) were seen exclusively in group II. In addition, in group II, there were no noticeable differences in the single sites treated with GM-CSF cDNA only compared with those receiving both gp100 and GM-CSF.
Systemic toxicity was assessed in patients following vaccine administration both by clinical exam and by standard clinical hematology and chemistry laboratory testing of blood samples (data not shown). No significant laboratory toxicities were noted in any patient following PMED. Additionally, none of the symptoms reported by the patients was greater than grade 2, and all toxicities either were unrelated or unlikely to be related to PMED. The most common complaints of patients were constitutional symptoms, especially fatigue and insomnia. Other symptoms that were reported include headache and pain in the back, neck, or joints. Patient 3 experienced an episode at the end of course 1 consisting of anorexia, decreased concentration, expressive aphasia, urinary incontinence, and vomiting. All of these symptoms for patient 3 were thought to be due to the development of brain metastases. Patient 12 developed an infection at the pre-study biopsy site, which was treated without complication with 7 days of oral dicloxacillin.
No additional significant clinical toxicities occurred during protocol therapy.
Antitumor effects
The best clinical response and the duration of that response for each patient are shown in Table 3 . Of the four patients who entered the study without evidence of disease, two remain disease-free as of their last follow-up visits. Of the eight patients who had clinically evaluable disease at the time of their enrollment, one patient (patient 2) had stable disease after receiving the study vaccinations; the remaining seven showed disease progression. At the time of study entry, patient 2 recently had discontinued a sequential biochemotherapy regimen due to treatment-related toxicity, despite an objective clinical response to this therapy. He continued with stable disease following his PMED protocol therapy.
Biological responses to vaccine
Autoimmune antibody production. Patients on this study were tested for a variety of serologic markers of autoimmunity (Table 4 ). ANA was used as a nonspecific indicator of autoimmunity. Two of three patients in the group II, dose 2 cohort showed a 4-fold titer increase in their ANA levels after receiving the first course of vaccinations; the third patient in this group was negative both before and after course 1. Similarly, two of three patients in group I, dose 1 converted from negative before vaccination to titers of 1:80 and 1:160 after one course (respectively), whereas the third patient showed a 2-fold titer increase in their ANA level after the first cycle. Patients in the other two study cohorts showed no more than a 2-fold titer change in either direction comparing prestudy ANA levels with levels after course 1.
As for the tissue-specific autoantibodies, patients did not show a clear pattern of induction in any of these markers (Table 4 ). Anti-ssDNA levels were detectable in 11 of 12 patients at nearly every time point tested. Three patients in two different study cohorts (patients 1, 9, and 11) showed modest increases in their anti-ssDNA levels after course 1 of vaccination compared with pre-study levels. Anti -smooth muscle antibodies were detected infrequently, and none of the titers was greater than 1:20 (i.e., within normal limits). Additionally, of the six remaining markers tested, positive results were seen in no more than one patient and at no more than two time points. One patient (patient 6) was positive for antimitochondrial antibodies both pre-study and after course 1 as well as ANA titers of 1:1,280 before vaccination and more than 1:1,280 (i.e., above the linear range of detection) following course 1.
Transgene expression in vaccine sites. For both treatment groups, vaccine sites were biopsied 2 days and 4 days after gp100 PMED. Due to early termination of the study, the last three patients enrolled in group II (patients 10-12) only had biopsies obtained on C1D6 (i.e., 2 days after gp100 vaccine), thus yielding a total of 27 vaccine sites. The expression of gp100 in selected vaccine sites was assessed by immunohistochemistry using the portion of the biopsies that was formalin fixed, paraffin embedded, and sectioned. Staining for gp100 in vaccine sites was not observed to a greater degree than that seen in normal skin (data not shown).
The expression of GM-CSF in vaccine sites receiving PMED was assessed by ELISA ( Fig. 1) . As a comparison, normal skin samples were available from all patients except patients 1 and 3. In this analysis, a sample was considered negative if the average concentration of the duplicate samples was below the average concentration of the normal skin samples (14.3 pg/mL; n = 10) plus two SDs (r 2 = 0.526); this produced a cutoff value of 15.4 pg/mL. Of the normal skin samples, 1 of 10 (10%) samples was tested above this cutoff and was 1  Stage IV  2  PD  -2  I  1  Stage IV  4  SD  33+  3  I  1  Stage IV  2  PD  -4  I  2  NED  4  NED  8  5  I  2  NED  4  NED  73+  6  I  2  Stage IV  2  PD  -7  II  1  Stage IV  2  PD  -8  II  1  Stage IV  2  PD  -9  II  1  NED  2  NED  61+  10  II  2  NED  1  NED  17  11  II  2  Stage IV  1  SD  1  12  II  2  Stage IV  1 considered positive. As for sites that received vaccine, 1 of 18 (5.6%) samples from group I was positive for GM-CSF, whereas 8 of 9 (88.9%) samples from group II were positive (P < 0.001). There were no clearly demonstrable changes in GM-CSF expression in biopsies obtained 2 days versus 4 days after vaccination.
Histology of biopsied vaccine sites. From each paraffinembedded vaccine site biopsy, one section was stained with H&E and reviewed by a dermatopathologist. The most common findings in vaccine site biopsies compared with normal skin biopsies included parakeratosis (retention of nuclei in the stratum corneum; a normal reaction by skin to injury) and a mononuclear cell infiltrate (data not shown). The mononuclear cell infiltrate was qualitatively more dramatic in biopsies from patients receiving GM-CSF cDNA in group II.
In addition, the depth of gold-bead penetration into skin was assessed. Beads were counted in individual MPFs to judge bead penetration beyond the stratum corneum. After combining the counts from all analyzed fields, 75.6% of beads were found in the stratum corneum, 8.3% were found in the malphigian layer, and 16.1% were found in the dermis (n = 4,942 beads in 34 combined MPFs). To evaluate the persistence in skin of the beads, we compared the percentage of beads per MPF found in these skin layers from biopsies collected 2 days after vaccination with those collected 4 days after vaccination. We found that in those 2 days, the proportion of beads in the epidermis decreased, whereas that of beads in the dermis increased (P = 0.049; Fig. 2A ). Additionally, we noted that patients in group II, who received two vaccines at the same site spaced 3 days apart, showed a highly significant reduction in the proportion of beads found in the dermis per MPF when compared with biopsies from group I (P < 0.001; Fig. 2B ). Because we did not have biopsy material from patients in group II at the day 29 time point (i.e., 4 days after vaccination), we restricted our analysis of these data to biopsies obtained 2 days after vaccination.
The presence of CD1a + dendritic cells also was assessed in the biopsy sites. Representative photomicrographs of these immunohistochemical experiments are shown in Fig. 3A to D. When the number of dendritic cells per MPF was counted in each available specimen, it was found that vaccine sites from Abbreviations: F/U, follow-up; 0, negative. * The following autoantibodies were negative in all patients at all time points tested, with any exception listed parenthetically: anti-dsDNA, rheumatoid factor (patient 11: <1:40 pre-study and at C1D43), anti-parietal cell (patient 1: positive at C1D43), anti-mitochondrial (patient 6: positive pre-study and at C1D43); anti-thyroglobulin; and anti-microsomal (patient 10: 1:100 at C1D43).
group I had significantly fewer dendritic cells than normal skin (P < 0.001) as well as vaccine sites from group II (P = 0.010). The difference between group II and normal skin bordered on significance (P = 0.058; Fig. 3E ).
Immunologic monitoring following vaccination. The immunologic monitoring was restricted to the HLA-A2(+) patients and included DTH testing (patients 1, 2, 6, and 8) and in vitro monitoring (patients 1, 2, and 6). As a marker of specific in vivo immune activation, DTH reactions to a gp100 peptide (210M) were measured. Three of these four patients showed either erythema or induration in response to the control antigens; patient 8 showed no response to either control antigen (data not shown). As for DTH response to the gp100 peptide, patient 2 had a 5 Â 5 -mm-indurated reaction to gp100 peptide (210M) during course 1, but no reaction was seen in course 2. The remaining three patients showed no response to gp100 at any time point.
The in vitro monitoring was assessed for cell-mediated immune responses following PMED that were melanoma reactive. One patient (patient 6) had an increase in the percentage of IFN-g -secreting Mel5-reactive T cells in their PBLs postvaccination compared with prevaccination levels (0.22% versus 0.079%; data not shown). There was no significant response over background in the remaining two patients (patients 1 and 2). PBLs from all three patients produced significant amounts of IFN-g in response to phorbol 12-myristate 13-acetate and ionomycin. No patient PBLs had a significant response to medium alone. In addition, as a marker of T-cell activation, we assessed expression of CD69 by PBLs. However, there was no significant detection of CD69 by flow cytometry in any patient sample (data not shown).
Discussion
This study is the first report of the clinical safety and biological activity of in vivo PMED as a cancer vaccine. Recent studies showed clinical safety and immunogenicity of PMED when used as a vaccine strategy for infectious disease (20 -22) . The potential use of DNA vaccination for cancer applications is a topic of ongoing investigation (19, 24, 25) . Because PMED has elicited strong immune responses in infectious disease clinical trials, it requires investigation in cancer applications. The cDNAs delivered by PMED were selected for their role in melanoma-specific immunity (gp100) and for use as a vaccine adjuvant (GM-CSF). Our results suggest that these genes, when administered by PMED, are tolerated well.
There were no dose-limiting toxicities, and the maximum tolerated dose of these vaccines was not assessed in this study. Toxicity to vaccination was limited to local skin reactions. These local skin reactions (i.e., erythema, pruritus, dry-scale formation, etc.) are similar to toxicities reported in other studies using PMED to administer vaccines into skin (20 -22) and were most likely due to transient skin injury caused by gold-bead penetration, although skin reactions to the transgenes cannot be excluded as a contributing factor. This should be considered in group II especially, where GM-CSF expression may have induced an inflammatory response. To our knowledge, this study also reports the first use of serologic monitoring for tissue-specific pathologic autoimmunity following DNA vaccination in humans; a search of the literature found one study of DNA vaccines for HIV where patients were monitored only for ANA and anti-DNA antibody production (26) . Vaccination with DNA carries with it the theoretical risk of induction of autoimmunity (27) . Although we did not see any clear evidence of specific autoimmune induction, we did see a trend in pre-study and post-course 1 ANA levels that may point toward a nonspecific autoimmune induction following DNA vaccination. It is interesting that one of the two study cohorts to suggest this trend (and perhaps the one cohort with the most clinically relevant increase) was the cohort that received the greatest number of vaccines: group II, dose 2. ANA testing represents the detection of autoantibodies to a multitude of nuclear and cytoplasmic antigens, and the trend showing an increased ANA titer supports a mild, nonspecific induction of autoimmunity after DNA vaccination in these patients.
Whereas ANA is considered a relatively nonspecific marker of autoimmunity, the other autoantibodies that were measured can be applied to specific autoimmune diseases. Anti-ssDNA was seen frequently (Table 4 ), but the level was highly variable between study cohorts and across treatment cycles, a pattern that is consistent with low-avidity, nonspecific autoantibodies. Overall, there was no clear induction of any pathologic autoantibodies in this study population. This is important, as a change in specific DNA or tissue autoantibodies would support a more directed antigen-driven change associated with DNA vaccination. There were no clinical toxicities to suggest any autoimmune toxicity.
From the vaccine site biopsies, we showed expression (using ELISA) of the GM-CSF transgene delivered into the skin by PMED. In contrast, gp100 could not be detected using immunohistochemistry. Because transgene expression following PMED likely is an infrequent event (28) , it is plausible that our inability to detect gp100 expression was due to the relatively small amount of tissue sampled on a tissue section for immunohistochemistry. Consistent with this concept is the finding that the majority of gold beads (75.6%) do not penetrate beyond the stratum corneum. This leaves relatively few beads to deliver the genes of interest to the living cells of skin, where transgene expression is able to occur.
The gold-bead counting in vaccine sites also showed two potentially important technical issues with PMED. The finding that a greater proportion of beads are found in the dermis overtime suggests that beads trapped in the epidermis are lost with the normal cycling of keratinocytes, adding significance to those beads that penetrate into the dermis. Of note, this observation as well as the finding that relatively few beads penetrate beyond the stratum corneum also were noted in a study using PMED to administer DNA for hepatitis B surface antigen in minipigs (28) . Additionally, when PMED is administered multiple times to the same site, bead penetration may be impaired. This was noted when biopsies on postvaccine day 2 were compared between the study groups. This is somewhat counterintuitive, as we expected more gold beads to be present in sites that were treated twice. One possible explanation for this observation is the increased mononuclear cells entering this site of vaccination; perhaps the increased cellular density prevented beads from reaching the deeper layers of the skin. Ultimately, it would seem that administration of multiple vaccines by PMED to the same skin site may be counterproductive in that fewer beads reach the living layers of skin compared with a single vaccine.
The immunohistochemical analysis of CD1a + dendritic cells in vaccine site biopsies also revealed several trends. First, the inclusion of cDNA for GM-CSF in the vaccine regimen led to a significantly greater influx of dendritic cells into the vaccine site than when this coding sequence was absent. These data corroborate biological activity of GM-CSF in skin following genetic vaccination. Another finding from the CD1a immunohistochemistry was that a single vaccination with cDNA for gp100 showed a decrease in the number of dendritic cells in the vaccine sites compared with normal skin. This supports our conclusions that PMED with cDNA for GM-CSF had a biological effect. One could argue that the cellular infiltrate that we found was a nonspecific response to tissue injury from H&E-stained sections of vaccine sites were examined under Â20 magnification, and the number of gold beads present per MPF was counted. Adequate tissue was not available for these analyses from patient 4 at C1D3 and C1D26, patient 5 at C2D3, and patients 7 to 9 at C1D6 and C1D29. A, proportion of beads in different skin layers 2 d (black columns) and 4 d (white columns) after PMED. P value shows the result of a one-sided Wilcoxon rank-sum test of the normalized proportion of beads present in the dermis at these two time points, as we are interested in the directional change. B, proportion of beads in the epidermis and dermis in vaccine sites 2 d after gp100 cDNA PMED from groups I (black columns) and II (white columns). P value shows the result of a two-sided Wilcoxon rank-sum test of the normalized proportion of beads penetrating into the dermis between two groups. the gold beads. If this was the case, however, we would expect to see more dendritic cells in the sites vaccinated with gp100 alone compared with normal skin and even more dendritic cells after two vaccinations. Because more dendritic cells were seen in the presence of GM-CSF (i.e., two vaccines) and fewer in its absence (i.e., one vaccine), it is more likely due to the proinflammatory effects of GM-CSF than a reaction to skin injury only. As for the finding that vaccine sites from group I had fewer dendritic cells than normal skin, preclinical work with PMED has suggested that dendritic cells present in skin before PMED may migrate out of the vaccine site into regional lymph nodes (29) . We did not obtain lymph node tissue to test this hypothesis; nevertheless, it is a possible explanation for this observation.
The immunologic monitoring done in this study suggested a modest melanoma-specific cellular immune response in one patient and a modest DTH response to a gp100 peptide in another patient. However, no patient showed an increase in activated T cells by induction of CD69 expression, and the DTH response was only transient, as the reaction to peptide was seen at the end of course 1 but not course 2. Thus, it is not known if the clinical response of stable disease in this study was the result of a vaccine-induced immune response. PMED has been shown previously to induce robust cellular immunity to hepatitis B surface antigen in healthy control patients (21) . Induction of humoral immunity has also been shown in previous efforts with PMED (20 -22) . More detailed immunologic monitoring would be needed to characterize the immunogenicity of PMED of gp100 and GM-CSF cDNAs in melanoma patients. However, this technology can also be used to deliver multiple transgenes to the same cell. Thus, subsequent clinical trials using PMED can evaluate codelivery of multiple plasmid vectors to enhance immunogenicity. This study was designed to evaluate this strategy (i.e., group III; see Materials and Methods), but early termination preempted enrollment of patients into this group.
In conclusion, PMED of cDNAs for gp100 and GM-CSF is safe and well tolerated when given in vivo to unaffected skin of patients with melanoma. In addition, this technique yields biologically active transgene expression in the treated sites. Although it is a theoretical concern of DNA vaccines, pathologic autoimmunity was not shown after PMED of gp100 and GM-CSF cDNAs. This is an important consideration for future strategies implementing gene-based therapy. Further Fig. 3 . Immunohistochemistry of skin biopsies for CD1a + cells following vaccination by PMED. Paraffin-embedded sections from normal skin and vaccine site biopsies were stained for CD1a, a marker specific to dendritic cells, using the LSAB2-HRP kit with 3,3 ¶-diaminobenzidine substrate (DAKO; see Materials and Methods for details). Adequate tissue was not available for these analyses from patient 4 at C1D3 and C1D26; patient 5 at C2D3; patients 7 to 9 at C1D6 and C1D29; and normal skin from patients 5, 10, and 11. Normal skin (A) and vaccine site treated with PMED containing cDNA for gp100 only (B) from patient 6 in group I. Normal skin (C) and vaccine site treated with PMED containing cDNA for gp100 and GM-CSF (D) from patient 12 in group II. Representative of the results seen within these respective groups. Magnification of all images, Â20. 
